FR2866570B1 - Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee - Google Patents

Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee

Info

Publication number
FR2866570B1
FR2866570B1 FR0401723A FR0401723A FR2866570B1 FR 2866570 B1 FR2866570 B1 FR 2866570B1 FR 0401723 A FR0401723 A FR 0401723A FR 0401723 A FR0401723 A FR 0401723A FR 2866570 B1 FR2866570 B1 FR 2866570B1
Authority
FR
France
Prior art keywords
metronidazole
preparation
pharmaceutical composition
treating skin
skin inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0401723A
Other languages
English (en)
Other versions
FR2866570A1 (fr
Inventor
Fabrizio Folfi
Irina Safonova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0401723A priority Critical patent/FR2866570B1/fr
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to KR1020067016587A priority patent/KR20060124706A/ko
Priority to BRPI0506551-8A priority patent/BRPI0506551A/pt
Priority to PCT/FR2005/000371 priority patent/WO2005089751A2/fr
Priority to RU2006133546/15A priority patent/RU2006133546A/ru
Priority to CA002553933A priority patent/CA2553933A1/fr
Priority to EP05729170A priority patent/EP1718295A2/fr
Priority to JP2006553619A priority patent/JP2007523134A/ja
Priority to AU2005224124A priority patent/AU2005224124A1/en
Priority to US10/590,078 priority patent/US20070281984A1/en
Priority to CNA2005800055732A priority patent/CN1921851A/zh
Publication of FR2866570A1 publication Critical patent/FR2866570A1/fr
Application granted granted Critical
Publication of FR2866570B1 publication Critical patent/FR2866570B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR0401723A 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee Expired - Fee Related FR2866570B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0401723A FR2866570B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee
AU2005224124A AU2005224124A1 (en) 2004-02-20 2005-02-17 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous inflammation
PCT/FR2005/000371 WO2005089751A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement d’une inflammation cutanee
RU2006133546/15A RU2006133546A (ru) 2004-02-20 2005-02-17 Применение метронидазола для получения фармацевтической композиции, предназначенной для лечения кожного воспаления
CA002553933A CA2553933A1 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement d'une inflammation cutanee
EP05729170A EP1718295A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement d'une inflammation cutanee
KR1020067016587A KR20060124706A (ko) 2004-02-20 2005-02-17 피부 염증 치료용 약학 조성물의 제조를 위한메트로니다졸의 용도
BRPI0506551-8A BRPI0506551A (pt) 2004-02-20 2005-02-17 uso do metronidazol para a preparação de uma composição farmacêutica
US10/590,078 US20070281984A1 (en) 2004-02-20 2005-02-17 Use Of Metronidazole For Preparing A Pharmaceutical Composition For Treating A Cutaneous Inflammation
CNA2005800055732A CN1921851A (zh) 2004-02-20 2005-02-17 甲硝唑在制备用于治疗皮肤炎症药物组合物中的用途
JP2006553619A JP2007523134A (ja) 2004-02-20 2005-02-17 皮膚炎症治療用の薬剤組成物を調製するためのメトロニダゾールの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0401723A FR2866570B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee

Publications (2)

Publication Number Publication Date
FR2866570A1 FR2866570A1 (fr) 2005-08-26
FR2866570B1 true FR2866570B1 (fr) 2007-08-24

Family

ID=34833947

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0401723A Expired - Fee Related FR2866570B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee

Country Status (11)

Country Link
US (1) US20070281984A1 (fr)
EP (1) EP1718295A2 (fr)
JP (1) JP2007523134A (fr)
KR (1) KR20060124706A (fr)
CN (1) CN1921851A (fr)
AU (1) AU2005224124A1 (fr)
BR (1) BRPI0506551A (fr)
CA (1) CA2553933A1 (fr)
FR (1) FR2866570B1 (fr)
RU (1) RU2006133546A (fr)
WO (1) WO2005089751A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108147A1 (fr) * 2008-02-27 2009-09-03 Qlt Usa, Inc. Dapsone pour traiter la rosacée

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
CA2161737C (fr) * 1995-10-30 1998-10-20 Richard J. Mackay Gel de metronidazole
GB9626513D0 (en) * 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
AU773881B2 (en) * 1999-07-16 2004-06-10 Shoei Co., Ltd. Nitroimidazole external preparations for dermatosis
JP2004532853A (ja) * 2001-05-09 2004-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 酒さを治療する目的での組成物の使用
ES2279391T3 (es) * 2003-06-18 2007-08-16 Galderma S.A. Composicion farmaceutica topica de tintura verde a base de metronidazol.

Also Published As

Publication number Publication date
EP1718295A2 (fr) 2006-11-08
CA2553933A1 (fr) 2005-09-29
CN1921851A (zh) 2007-02-28
JP2007523134A (ja) 2007-08-16
RU2006133546A (ru) 2008-03-27
US20070281984A1 (en) 2007-12-06
KR20060124706A (ko) 2006-12-05
AU2005224124A1 (en) 2005-09-29
FR2866570A1 (fr) 2005-08-26
WO2005089751A2 (fr) 2005-09-29
BRPI0506551A (pt) 2007-02-27
WO2005089751A3 (fr) 2005-12-08

Similar Documents

Publication Publication Date Title
FR2867778B1 (fr) Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
FR14C0020I1 (fr) Compositions pharmaceutiques contenant du fentanyl pour application nasale
NO20044054L (no) Administrering av midler for behandling av betennelse
FR2871696B1 (fr) Composition topique pour le traitement du psoriasis
FR2915102B1 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
FR13C0044I2 (fr) Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR2879914B1 (fr) Ecarteur-retenteur d'intestins pour chirurgie coelioscopique
FR2871693B1 (fr) Utilisation d'une composition pharmaceutique comprenant du calcitriol et du propionate de clobetasol pour le traitement du psoriasis
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2911507B1 (fr) Utilisation de lignanes et/ou pour l'obtention d'une composition pharmaceutique, cosmetique, dermatologique et/ou neutraceutique
FR2866570B1 (fr) Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter une inflammation cutanee
FR2908995B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
FR2866568B1 (fr) Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter un desordre de la vascularisation cutanee
FR2862537B1 (fr) Utilisation du fepradinol pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
FR2894144B1 (fr) Utilisation du dipeptide tyrosine-arginine dans une composition cosmetique ou pour la preparation d'un medicament
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2861300B1 (fr) Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2875404B1 (fr) Composition pharmaceutique pour le traitement de la rosacee
FR2837708B1 (fr) Utilisation de la 8'-hydroxydihydroergotamine pour la fabrication d'un medicament contre la migraine
FR2908994B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire
FR2885300B1 (fr) Composition topique pour la protection de l'epiderme
ITMI20011284A0 (it) Composizione farmaceutica per il trattamento dell'iperfosfatemia
MA28513B1 (fr) Processus pour la preparation d'inhibiteurs de tryptase
FR2852242B1 (fr) Utilisation d'oligogalacturonides en cosmetique ou pour la preparation d'une composition dermatologique ou pharmaceutique

Legal Events

Date Code Title Description
CA Change of address
ST Notification of lapse

Effective date: 20081031